匹伐他汀联合阿加曲班对急性脑梗死患者的临床疗效观察  

Clinical observation of pitavastatin combined with argatroban on patients with acute cerebral infarction

作　　者：韩健 陈志强 付雪萍 Han Jian;Chen Zhiqiang;Fu Xueping(Department of Pharmacy,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京佑安医院药学部,100069 [2]北京大兴镇中心卫生院医务科

出　　处：《北京医学》2023年第12期1028-1032,共5页Beijing Medical Journal

摘　　要：目的 探讨匹伐他汀联合阿加曲班治疗急性脑梗死(acute cerebral infarction, ACI)患者的疗效。方法 选取2020年10月至2022年3月首都医科大学附属北京佑安医院ACI患者120例,随机分为对照组和研究组,每组60例。对照组给予常规治疗+阿加曲班+阿托伐他汀,研究组给予常规治疗+阿加曲班+匹伐他汀。比较两组患者临床治疗总有效率、LDL-C、颈动脉内膜中层厚度(intima-media thickness, IMT)、内皮素(endothelin, ET)、一氧化氮(nitric oxide,NO)、降钙素基因相关肽(calcitonin gene-related peptide, CGRP)、人脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2, Lp-PLA2)、金属蛋白酶9(metalloproteinase 9, MMP-9)、同型半胱氨酸(homocysteine, Hcy)、丙二醛(malonyldialdehyde, MDA)和髓磷脂碱性蛋白(myelin basic protein, MBP)。结果 120例ACI患者中,男65例,女55例,年龄34~79岁,平均(58.9±3.4)岁。研究组临床治疗总有效率高于对照组(86.66%比73.33%),差异有统计学意义(P<0.05)。两组治疗前各实验室指标、治疗前后颈动脉IMT的比较,差异均无统计学意义(P> 0.05)。两组治疗后LDL-C、ET、Lp-PLA2、MMP-9、Hcy、MDA和MBP均低于治疗前,NO和CGRP均高于治疗前;研究组治疗后LDL-C、ET、Lp-PLA2、MMP-9、Hcy、MDA和MBP低于对照组,NO和CGRP高于对照组,差异均有统计学意义(P <0.05)。结论 匹伐他汀联合阿加曲班可以显著提高ACI患者的临床疗效,降低血清MDA、MBP水平。Objective To explore the efficacy of pitavastatin combined with argatroban in the treatment of patients with acute cerebral infarction(ACI).Methods A total of 120 patients with ACI in Beijing Youan Hospital affiliated to Capital Medical University from October 2020 to March 2022 were selected,and were randomly divided into control group and research group,with 60 patients in each group.The control group was given conventional treatment+argatroban+atorvastatin,while the research group was given conventional treatment+argatroban+pitavastatin.The total effective rate of clinical treatment,LDL-C,intima-media thickness(IMT),endothelin(ET),nitric oxide(NO),calcitonin gene-related peptide(CGRP),lipoprotein-associated phospholipase A2(Lp-PLA2),metalloprotease 9(MMP-9),homocysteine(Hcy),malonyldialdehyde(MDA)and myelin basic protein(MBP)were compared between the two groups.Results Among the 120 patients with ACI,there were 65 males and 55 females,aged from 34 to 79 years,with an average age of(58.9±3.4)years.The total effective rate of clinical treatment in the research group was higher than that of the control group(86.66%vs.73.33%),and the difference was statistically significant(P<0.05).There was no significant difference in laboratory indexes and carotid IMT before and after treatment between the two groups(P>0.05).After treatment,LDL-C,ET,Lp-PLA2,MMP-9,Hcy,MDA and MBP in both groups were lower than those before treatment,while NO and CGRP were higher than those before treatment.After treatment,LDL-C,ET,Lp-PLA2,MMP-9,Hcy,MDA and MBP in the research group were lower than those in the control group,while NO and CGRP were higher than those in the control group,the differences were statistically significant(P<0.05).Conclusions Pitavastatin combined with argatroban can significantly improve the clinical efficacy of patients with ACI and reduce the influence of serum MDA and MBP levels.

关 键 词：匹伐他汀 阿加曲班 急性脑梗死 丙二醛 髓磷脂碱性蛋白 

分 类 号：R743.33[医药卫生—神经病学与精神病学]